nach oben

Erschienen in:

01.08.2019 | Review Article

A comprehensive review of rituximab therapy in rheumatoid arthritis patients

verfasst von: Soheil Tavakolpour, Samira Alesaeidi, Mohammad Darvishi, Mojtaba GhasemiAdl, Sahar Darabi-Monadi, Meisam Akhlaghdoust, Somayeh Elikaei Behjati, Arash Jafarieh

Erschienen in: Clinical Rheumatology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Rituximab (RTX) is an approved treatment for rheumatoid arthritis (RA) patients that do not respond adequately to disease-modifying antirheumatic drugs. However, different new concerns, such as efficacy, optimum dose, safety issues, prediction of response to RTX, and pregnancy outcomes have attracted a lot of attention. The PubMed database was systematically reviewed for the last published articles, new findings, and controversial issues regarding RTX therapy in RA using “Rheumatoid arthritis” AND “rituximab” keywords, last updated on June 18, 2019. From 1812 initial recorders, 162 studies met the criteria. Regarding the optimum dose, low-dose RTX therapy (2 × 500 mg) seems as effective as standard dose (2 × 1000 mg), safer, and more cost-effective. The most common reported safety challenges included de novo infections, false negative serologic tests of viral infections, reactivation of chronic infections, interfering with vaccination outcome, and development of de novo psoriasis. Other less reported side effects are infusion reactions, nervous system disorders, and gastrointestinal disorders. Lower exposure to other biologics, presence of some serological markers (e.g., anti-RF, anti-CCP, IL-33, ESR), specific variations in FCGR3A, FCGR2A, TGFβ1, IL6, IRF5, BAFF genes, and also EBV-positivity could be used to predict response to RTX. Although there is no evidence of the teratogenic effect of RTX, it is recommended that women do not expose themselves to RTX at least 6 months before the conception. Only a reversible reduction of B cell-count in the offspring may be the pregnancy-related outcome. Although RTX is an effective therapeutic option for RA, more studies on optimum doses, prevention of RTX-related side effects, prediction of RTX response, and safety during the pregnancy are required.

van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41(10):1845–1850. https://doi.org/10.1002/1529-0131(199810)41:10<1845::aid-art17>3.0.co;2-k CrossRefPubMed

Derksen VFAM, Huizinga TWJ, van der Woude D (2017) The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol 39(4):437–446. https://doi.org/10.1007/s00281-017-0627-z CrossRefPubMedPubMedCentral

Wijbrandts CA, Tak PP (2017) Prediction of response to targeted treatment in rheumatoid arthritis. Mayo Clin Proc 92(7):1129–1143. https://doi.org/10.1016/j.mayocp.2017.05.009 CrossRefPubMed

Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K (2018) Rheumatoid arthritis. Nat Rev Dis Primers 4:18001. https://doi.org/10.1038/nrdp.2018.1 CrossRefPubMed

Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, Strangfeld A (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFalpha inhibitors and rituximab. Ann Rheum Dis 74(2):415–421. https://doi.org/10.1136/annrheumdis-2013-204021 CrossRefPubMed

Clark E, Ledbetter J (2005) How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis 64(Suppl 4):iv77–iv80. https://doi.org/10.1136/ard.2005.042507 CrossRefPubMedPubMedCentral

Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC (2006) Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54(3):723–732. https://doi.org/10.1002/art.21650 CrossRefPubMed

Melet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G (2013) Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum 65(11):2783–2790. https://doi.org/10.1002/art.38107 CrossRefPubMed

Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T, Ferraccioli G, Gottenberg JE, Isaacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, van der Heijde D, van Vollenhoven RF, Emery P (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70(6):909–920. https://doi.org/10.1136/ard.2010.144998 CrossRefPubMed

10.

van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, Tyson N, Collinson N, Lehane PB (2013) Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72(9):1496–1502. https://doi.org/10.1136/annrheumdis-2012-201956 CrossRefPubMed

11.

Nicholls D, Zochling J, Boers A, Champion G, Mathers D, Riordan J, Youssef P, Scott J, Griffiths H (2014) A retrospective chart review of the use of rituximab for the treatment of rheumatoid arthritis in Australian rheumatology practice. Int J Rheum Dis 17(7):755–761. https://doi.org/10.1111/1756-185x.12164 CrossRefPubMed

12.

Aaltonen KJ, Joensuu JT, Virkki L, Sokka T, Aronen P, Relas H, Valleala H, Rantalaiho V, Pirila L, Puolakka K, Uusitalo T, Blom M, Konttinen YT, Nordstrom D (2015) Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy. J Rheumatol 42(3):372–378. https://doi.org/10.3899/jrheum.140853 CrossRefPubMed

13.

van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB (2015) Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol 42(10):1761–1766. https://doi.org/10.3899/jrheum.150051 CrossRefPubMed

14.

Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, Ogale S, Armstrong G, Jahreis A, Burke L, Mela C, Chen A (2011) Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res (Hoboken) 63(5):711–720. https://doi.org/10.1002/acr.20419 CrossRef

15.

Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54(9):2793–2806. https://doi.org/10.1002/art.22025 CrossRefPubMed

16.

Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54(5):1390–1400. https://doi.org/10.1002/art.21778 CrossRefPubMed

17.

Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM (2005) Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J Rheumatol 32(11):2109–2115PubMed

18.

Ho LY, Mok CC, To CH, Anselm M, Cheung MY, Yu KL (2007) Rituximab for refractory rheumatoid arthritis: a 24-week open-label prospective study. Open Rheumatol J 1:1–4. https://doi.org/10.2174/1874312900701010001 CrossRefPubMedPubMedCentral

19.

Moore J, Ma D, Will R, Cannell P, Handel M, Milliken S (2004) A phase II study of rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplant 34(3):241–247. https://doi.org/10.1038/sj.bmt.1704570 CrossRefPubMed

20.

Jois RN, Masding A, Somerville M, Gaffney K, Scott DG (2007) Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience. Rheumatology (Oxford) 46(6):980–982. https://doi.org/10.1093/rheumatology/kel453 CrossRef

21.

Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, Tak PP, Broder MS, Yu E, Cravets M, Magrini F, Jost F (2008) Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 59(6):785–793. https://doi.org/10.1002/art.23715 CrossRefPubMed

22.

Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM (2012) Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology biologics register. Arthritis Care Res (Hoboken) 64(8):1108–1115. https://doi.org/10.1002/acr.21663 CrossRef

23.

Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, Munro R, McLaren J, McRorie E, Packham J, Buckley CD, Harvie J, Taylor P, Choy E, Pitzalis C, McInnes IB (2016) Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet 388(10041):239–247. https://doi.org/10.1016/s0140-6736(16)00380-9 CrossRefPubMed

24.

Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, Hessey E, Chen A, Tyrrell H, Shaw TM (2011) Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70(1):39–46. https://doi.org/10.1136/ard.2010.137703 CrossRefPubMed

25.

Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, Healy E, Hessey E, Reynard M, Shaw T (2012) Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 71(3):351–357. https://doi.org/10.1136/annrheumdis-2011-200170 CrossRefPubMed

26.

Harrold LR, John A, Best J, Zlotnick S, Karki C, Li Y, Greenberg JD, Kremer JM (2017) Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry. Clin Rheumatol 36(9):2135–2140. https://doi.org/10.1007/s10067-017-3742-2 CrossRefPubMedPubMedCentral

27.

Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, Flipo RM, Saraux A, Schaeverbeke T, Sibilia J, Soubrier M, Vittecoq O, Baron G, Constantin A, Ravaud P, Mariette X (2019) Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. Bmj 364:l67. https://doi.org/10.1136/bmj.l67 CrossRefPubMedPubMedCentral

28.

Coutant F, Rouzaire P, Soubrier M (2017) An unexpected response to rituximab in a patient with rheumatoid arthritis. Rheumatology (Oxford) 57:580–582. https://doi.org/10.1093/rheumatology/kex418 CrossRef

29.

Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP (2007) Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 56(3):772–778. https://doi.org/10.1002/art.22400 CrossRefPubMed

30.

Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, Koutala H, Papadaki HA, Kritikos H, Boumpas DT (2009) Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 11(4):R131. https://doi.org/10.1186/ar2798 CrossRefPubMedPubMedCentral

31.

Vital EM, Dass S, Rawstron AC, Buch MH, Goeb V, Henshaw K, Ponchel F, Emery P (2010) Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 62(5):1273–1279. https://doi.org/10.1002/art.27359 CrossRefPubMed

32.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordstrom DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF (2011) Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 70(9):1575–1580. https://doi.org/10.1136/ard.2010.148759 CrossRefPubMed

33.

Narvaez J, Diaz-Torne C, Ruiz JM, Hernandez MV, Torrente-Segarra V, Ros S, Rodriguez de la Serna A, Diaz-Lopez C, Sanmarti R, Nolla JM (2011) Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. Clin Exp Rheumatol 29(6):991–997PubMed

34.

De Keyser F, Hoffman I, Durez P, Kaiser MJ, Westhovens R (2014) Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry. J Rheumatol 41(9):1761–1765. https://doi.org/10.3899/jrheum.131279 CrossRefPubMed

35.

Harrold LR, Reed GW, Shewade A, Magner R, Saunders KC, John A, Kremer JM, Greenberg JD (2015) Effectiveness of rituximab for the treatment of rheumatoid arthritis in patients with prior exposure to anti-TNF: results from the CORRONA registry. J Rheumatol 42(7):1090–1098. https://doi.org/10.3899/jrheum.141043 CrossRefPubMed

36.

Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M, Morassi P, Masolini P, Pellerito R, Cutolo M, Puttini PS, De Vita S (2009) Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 48(12):1557–1559. https://doi.org/10.1093/rheumatology/kep314 CrossRef

37.

Valleala H, Korpela M, Hienonen-Kempas T, Immonen K, Lahteenmaki J, Uusitalo T, Komulainen R, Mottonen T, Hannonen P (2015) Long-term real-life experience with rituximab in adult Finnish patients with rheumatoid arthritis refractory or with contraindication to anti-tumor necrosis factor drugs. J Clin Rheumatol 21(1):24–30. https://doi.org/10.1097/rhu.0000000000000166 CrossRefPubMed

38.

Wang KC, Liao HT, Chen WS, Lai CC, Chou CT, Chen MH, Tsai CY (2019) Real-world effectiveness and safety of rituximab in the treatment of rheumatoid arthritis: a single-center experience in Taiwan. Int J Rheum Dis 22(5):860–868. https://doi.org/10.1111/1756-185x.13511 CrossRefPubMed

39.

Arts EE, Jansen TL, Den Broeder A, Vonkeman HE, Dutmer E, Van de Laar MA, Van Riel PL, Fransen J (2011) Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch rheumatoid arthritis monitoring (DREAM) registry. Ann Rheum Dis 70(5):877–878. https://doi.org/10.1136/ard.2010.136093 CrossRefPubMed

40.

Das S, Fernandez Matilla M, Dass S, Buch MH, Rawstron AC, Vital EM, Emery P (2013) Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis. Ann Rheum Dis 72(3):463–464. https://doi.org/10.1136/annrheumdis-2012-202454 CrossRefPubMed

41.

Mazilu D, Gudu T, Ionescu R, Opris D (2014) Statins do not influence long-term rituximab clinical efficiency in rheumatoid arthritis patients. Biomed Res Int 2014:689426–689424. https://doi.org/10.1155/2014/689426 CrossRefPubMedPubMedCentral

42.

Lehane PB, Lacey S, Hessey EW, Jahreis A (2014) Effect of concomitant statins on rituximab efficacy in patients with rheumatoid arthritis. Ann Rheum Dis 73(10):1906–1908. https://doi.org/10.1136/annrheumdis-2014-205474 CrossRefPubMed

43.

Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K, Abud-Mendoza C, Szczepanski LJ, Roschmann RA, Chen A, Armstrong GK, Douglass W, Tyrrell H (2010) Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 69(9):1629–1635. https://doi.org/10.1136/ard.2009.119933 CrossRefPubMed

44.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordstrom DC, Gabay C, Canhao H, Tomsic M, van Riel PL, Gomez-Reino J, Kvien TK, van Vollenhoven RF (2016) Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther 18:50. https://doi.org/10.1186/s13075-016-0951-z CrossRefPubMedPubMedCentral

45.

Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreno L, Armstrong G, Collinson N, Shaw TM (2010) Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 49(9):1683–1693. https://doi.org/10.1093/rheumatology/keq116 CrossRef

46.

Bredemeier M, de Oliveira FK, Rocha CM (2014) Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 66(2):228–235. https://doi.org/10.1002/acr.22116 CrossRef

47.

Bredemeier M, Campos GG, de Oliveira FK (2015) Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis. Clin Rheumatol 34(10):1801–1805. https://doi.org/10.1007/s10067-015-2977-z CrossRefPubMed

48.

Henry J, Gottenberg JE, Rouanet S, Pavy S, Sellam J, Tubach F, Belkhir R, Mariette X, Seror R (2017) Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection. Rheumatology (Oxford) 57:538–547. https://doi.org/10.1093/rheumatology/kex446 CrossRef

49.

Mena-Vazquez N, Manrique-Arija S, Urena-Garnica I, Romero-Barco CM, Jimenez-Nunez FG, Coret V, Irigoyen-Oyarzabal MV, Fernandez-Nebro A (2016) Eficiency of different doses of rituximab in rheumatoid arthritis. Reumatol Clin 12(3):139–145. https://doi.org/10.1016/j.reuma.2015.07.003 CrossRefPubMed

50.

Mariette X, Rouanet S, Sibilia J, Combe B, Le Loet X, Tebib J, Jourdan R, Dougados M (2014) Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis 73(8):1508–1514. https://doi.org/10.1136/annrheumdis-2013-203480 CrossRefPubMed

51.

Chatzidionysiou K, Lie E, Lukina G, Hetland ML, Hauge EM, Pavelka K, Gabay C, Scherer A, Nordstrom D, Canhao H, Santos MJ, Tomsic M, Rotar Z, Hernandez MV, Gomez-Reino J, Ancuta I, Kvien TK, van Vollenhoven R (2017) Rituximab retreatment in rheumatoid arthritis in a real-life cohort: data from the CERERRA collaboration. J Rheumatol 44(2):162–169. https://doi.org/10.3899/jrheum.160460 CrossRefPubMed

52.

Schapink L, Nd B, Ad B, Verhoef L (2019) AB0408 fixed-interval versus on-demand retreatment strategy with rituximab in rheumatoid arthritis: a retrospective cohort study. Ann Rheum Dis 78(Suppl 2):1664–1665. https://doi.org/10.1136/annrheumdis-2019-eular.6215 CrossRef

53.

Vital EM, Dass S, Buch MH, Rawstron AC, Emery P (2015) An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. Ann Rheum Dis 74(6):1195–1201. https://doi.org/10.1136/annrheumdis-2013-204544 CrossRefPubMed

54.

Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56(12):3896–3908. https://doi.org/10.1002/art.23059 CrossRefPubMed

55.

Bastian H, Zinke S, Egerer K, Breuer S, Safari F, Burmester GR, Feist E (2010) Effects of early rituximab retreatment in rheumatoid arthritis patients with an inadequate response after the first cycle: retrospective arthritis cohort study. J Rheumatol 37(5):1069–1071. https://doi.org/10.3899/jrheum.091127 CrossRefPubMed

56.

Pritchard CH, Greenwald MW, Kremer JM, Gaylis NB, Rigby W, Zlotnick S, Chung C, Jaber B, Reiss W (2014) Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study. BMC Musculoskelet Disord 15:177. https://doi.org/10.1186/1471-2474-15-177 CrossRefPubMedPubMedCentral

57.

Winthrop KL, Saag K, Cascino MD, Pei J, John A, Jahreis A, Haselkorn T, Furst DE (2018) Long-term safety of rituximab in rheumatoid arthritis: analysis from the SUNSTONE registry. Arthritis Care Res (Hoboken). https://doi.org/10.1002/acr.23781

58.

Gron KL, Arkema EV, Glintborg B, Mehnert F, Ostergaard M, Dreyer L, Norgaard M, Krogh NS, Askling J, Hetland ML (2019) Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. Ann Rheum Dis 78(3):320–327. https://doi.org/10.1136/annrheumdis-2018-214326 CrossRefPubMed

59.

Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo RM, Godeau B, Guillevin L, Le Loet X, Hachulla E, Schaeverbeke T, Sibilia J, Baron G, Mariette X (2010) Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 62(9):2625–2632. https://doi.org/10.1002/art.27555 CrossRefPubMed

60.

Goates C, Tsuha S, Working S, Carey J, Spivak ES (2017) Seronegative West Nile virus infection in a patient treated with rituximab for rheumatoid arthritis. Am J Med 130(6):e257–e258. https://doi.org/10.1016/j.amjmed.2017.01.014 CrossRefPubMed

61.

Raffalli J, Wormser GP (2016) Persistence of babesiosis for >2 years in a patient on rituximab for rheumatoid arthritis. Diagn Microbiol Infect Dis 85(2):231–232. https://doi.org/10.1016/j.diagmicrobio.2016.02.016 CrossRefPubMed

62.

Ghrenassia E, Mekinian A, Rouaghe S, Ganne N, Fain O (2012) Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis. Joint Bone Spine 79(1):100–101. https://doi.org/10.1016/j.jbspin.2011.07.003 CrossRefPubMed

63.

Gigi E, Georgiou T, Mougiou D, Boura P, Raptopoulou-Gigi M (2013) Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab. Hippokratia 17(1):91–93PubMedPubMedCentral

64.

Salman-Monte TC, Lisbona MP, Garcia-Retortillo M, Maymo J (2014) Reactivation of hepatitis virus B infection in a patient with rheumatoid arthritis after treatment with rituximab. Reumatol Clin 10(3):196–197. https://doi.org/10.1016/j.reuma.2013.05.011 CrossRefPubMed

65.

Tien YC, Yen HH, Chiu YM (2017) Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis. Clin Exp Rheumatol 35(5):831–836PubMed

66.

Chen YM, Chen HH, Huang WN, Chen YH, Hsieh TY, Yang SS, Lan JL, Chen DY (2019) Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: a long-term, real-world observation. Int J Rheum Dis. https://doi.org/10.1111/1756-185x.13582

67.

Lin KM, Lin JC, Tseng WY, Cheng TT (2013) Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis. J Microbiol Immunol Infect 46(1):65–67. https://doi.org/10.1016/j.jmii.2011.12.020 CrossRefPubMed

68.

Chen YM, Chen HH, Chen YH, Hsieh TY, Hsieh CW, Hung WT, Lan JL, Chen DY (2015) A comparison of safety profiles of tumour necrosis factor alpha inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C. Ann Rheum Dis 74(3):626–627. https://doi.org/10.1136/annrheumdis-2014-206711 CrossRefPubMed

69.

Rehnberg M, Brisslert M, Amu S, Zendjanchi K, Hawi G, Bokarewa MI (2010) Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther 12(3):R111. https://doi.org/10.1186/ar3047 CrossRefPubMedPubMedCentral

70.

van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M (2010) Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 62(1):75–81. https://doi.org/10.1002/art.25033 CrossRefPubMed

71.

Intongkam S, Samakarnthai P, Pakchotanon R, Narongroeknawin P, Assavatanabodee P, Chaiamnuay S (2018) Efficacy and safety of hepatitis B vaccination in rheumatoid arthritis patients receiving disease-modifying Antirheumatic drugs and/or biologics therapy. J Clin Rheumatol:1. https://doi.org/10.1097/rhu.0000000000000877

72.

Dass S, Vital EM, Emery P (2007) Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 56(8):2715–2718. https://doi.org/10.1002/art.22811 CrossRefPubMed

73.

Hardcastle SA, Gibbs S, Williamson L (2012) Atypical psoriasis following rituximab for rheumatoid arthritis. J Rheumatol 39(6):1303–1304. https://doi.org/10.3899/jrheum.111256 CrossRefPubMed

74.

Guidelli GM, Fioravanti A, Rubegni P, Feci L (2013) Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature. Rheumatol Int 33(11):2927–2930. https://doi.org/10.1007/s00296-012-2581-3 CrossRefPubMed

75.

Ozen G, Ergun T, Oner SY, Demirkesen C, Inanc N (2013) Widespread psoriasis induced by rituximab in a patient with rheumatoid arthritis: an unexpected adverse reaction. Joint Bone Spine 80(5):545–547. https://doi.org/10.1016/j.jbspin.2013.02.001 CrossRefPubMed

76.

Brunasso AM, Massone C (2012) Plantar pustulosis during rituximab therapy for rheumatoid arthritis. J Am Acad Dermatol 67(4):e148–e150. https://doi.org/10.1016/j.jaad.2011.12.010 CrossRefPubMed

77.

Bhalme M, Hayes S, Norton A, Lal S, Chinoy H, Paine P (2013) Rituximab-associated colitis. Inflamm Bowel Dis 19(3):E41–E43. https://doi.org/10.1002/ibd.22963 CrossRefPubMed

78.

van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37(3):558–567. https://doi.org/10.3899/jrheum.090856 CrossRefPubMed

79.

Harrold LR, Reed GW, Karki C, Magner R, Shewade A, John A, Kremer JM, Greenberg JD (2016) Risk of infection associated with subsequent biologic agent use after rituximab: results from a National Rheumatoid Arthritis Patient registry. Arthritis Care Res (Hoboken) 68(12):1888–1893. https://doi.org/10.1002/acr.22912 CrossRef

80.

Silva-Fernandez L, De Cock D, Lunt M, Low AS, Watson KD, Symmons DPM, Hyrich KL (2017) Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Rheumatology (Oxford) 57:1533–1540. https://doi.org/10.1093/rheumatology/kex304 CrossRef

81.

Shi Y, Wu Y, Ren Y, Jiang Y, Chen Y (2019) Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis. https://doi.org/10.1111/1756-185x.13596

82.

Meyer A, Theulin A, Chatelus E, Argemi X, Sordet C, Javier RM, Hansmann Y, Sibilia J, Gottenberg JE (2012) Campylobacter fetus infection in three rheumatoid arthritis patients treated with rituximab. Ann Rheum Dis 71(6):1094–1095. https://doi.org/10.1136/annrheumdis-2011-200719 CrossRefPubMed

83.

Ottaviani S, Tiendrebeogo J, Choudat L, Gill G, Palazzo E, Meyer O, Dieude P (2013) Knee tuberculosis under rituximab therapy for rheumatoid arthritis. Joint Bone Spine 80(4):435–436. https://doi.org/10.1016/j.jbspin.2012.10.018 CrossRefPubMed

84.

Rouil A, Pollet S, Martin A, Tattevin P, Perdriger A (2013) Severe Pasteurella multocida infection in a patient on rituximab therapy for rheumatoid arthritis. Joint Bone Spine 80(2):224–225. https://doi.org/10.1016/j.jbspin.2012.07.011 CrossRefPubMed

85.

Santos VA, Tobon GJ, Canas CA (2018) Development of bronchiectasis during long-term rituximab treatment for rheumatoid arthritis. Adv Respir Med. https://doi.org/10.5603/ARM.a2018.0050

86.

Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, Perry A, Yerra R, Schmidt R, Alvarez E, Tyler KL (2011) Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68(9):1156–1164. https://doi.org/10.1001/archneurol.2011.103 CrossRefPubMedPubMedCentral

87.

Abdulkader R, Dharmapalaiah C, Rose G, Shand LM, Clunie GP, Watts RA (2014) Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab. J Rheumatol 41(5):858–861. https://doi.org/10.3899/jrheum.130526 CrossRefPubMed

88.

Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S (2011) Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 31(3):403–404. https://doi.org/10.1007/s00296-009-1202-2 CrossRefPubMed

89.

Varisco V, Vigano M, Batticciotto A, Lampertico P, Marchesoni A, Gibertini P, Pellerito R, Rovera G, Caporali R, Todoerti M, Covelli M, Notarnicola A, Atzeni F, Sarzi-Puttini P (2016) Low risk of hepatitis B virus reactivation in HBsAg-negative/anti-HBc-positive carriers receiving rituximab for rheumatoid arthritis: a retrospective multicenter Italian study. J Rheumatol 43(5):869–874. https://doi.org/10.3899/jrheum.151105 CrossRefPubMed

90.

Clavel G, Moulignier A, Semerano L (2017) Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments. Joint Bone Spine 84(6):671–675. https://doi.org/10.1016/j.jbspin.2017.03.002 CrossRefPubMed

91.

Burr ML, Malaviya AP, Gaston JH, Carmichael AJ, Ostor AJ (2008) Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis. Rheumatology (Oxford) 47(5):738–739. https://doi.org/10.1093/rheumatology/ken113 CrossRef

92.

Jung N, Owczarczyk K, Hellmann M, Lehmann C, Fatkenheuer G, Hallek M, Rubbert A (2008) Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis. Rheumatology (Oxford) 47(6):932–933. https://doi.org/10.1093/rheumatology/ken143 CrossRef

93.

Pehlivan Y, Kisacik B, Bosnak VK, Onat AM (2013) Rituximab seems to be a safer alternative in patients with active rheumatoid arthritis with tuberculosis. BMJ Case Rep 2013:bcr2012006585. https://doi.org/10.1136/bcr-2012-006585 CrossRefPubMedPubMedCentral

94.

Magnusson M, Brisslert M, Zendjanchi K, Lindh M, Bokarewa MI (2010) Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment. Rheumatology (Oxford) 49(10):1911–1919. https://doi.org/10.1093/rheumatology/keq159 CrossRef

95.

Gelinck LB, Teng YK, Rimmelzwaan GF, van den Bemt BJ, Kroon FP, van Laar JM (2007) Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 66(10):1402–1403. https://doi.org/10.1136/ard.2007.071878 CrossRefPubMedPubMedCentral

96.

Thomas L, Canoui-Poitrine F, Gottenberg JE, Economu-Dubosc A, Medkour F, Chevalier X, Bastuji-Garin S, Le Louet H, Farrenq V, Claudepierre P (2012) Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry. J Rheumatol 39(5):893–898. https://doi.org/10.3899/jrheum.111347 CrossRefPubMed

97.

Vasconcellos JB, Pereira DD, Vargas TJ, Levy RA, Pinheiro GD, Cursi IB (2016) Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis. An Bras Dermatol 91(5 suppl 1):137–139. https://doi.org/10.1590/abd1806-4841.20164456 CrossRefPubMedPubMedCentral

98.

Fui A, Bergantini L, Selvi E, Mazzei MA, Bennett D, Pieroni MG, Rottoli P, Bargagli E (2019) Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis. Intern Med J. https://doi.org/10.1111/imj.14306

99.

Md Yusof MY, Kabia A, Darby M, Lettieri G, Beirne P, Vital EM, Dass S, Emery P (2017) Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years’ experience at a single Centre. Rheumatology (Oxford) 56(8):1348–1357. https://doi.org/10.1093/rheumatology/kex072 CrossRef

100.

Paul F, Cartron G (2019) Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol 15(4):383–389. https://doi.org/10.1080/1744666x.2019.1562905 CrossRefPubMed

101.

Salmon JH, Perotin JM, Morel J, Drame M, Cantagrel A, Ziegler LE, Ravaud P, Sibilia J, Pane I, Mariette X, Gottenberg JE (2018) Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data. Rheumatology (Oxford) 57(1):134–139. https://doi.org/10.1093/rheumatology/kex403 CrossRef

102.

Wheater G, Elshahaly M, Naraghi K, Tuck SP, Datta HK, van Laar JM (2018) Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study. PLoS One 13(8):e0201527. https://doi.org/10.1371/journal.pone.0201527 CrossRefPubMedPubMedCentral

103.

Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, Jayne DR (2015) Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 57:60–65. https://doi.org/10.1016/j.jaut.2014.11.009 CrossRefPubMed

104.

Wijetilleka S, Mukhtyar C, Jayne D, Ala A, Bright P, Chinoy H, Harper L, Kazmi M, Kiani-Alikhan S, Li C, Misbah S, Oni L, Price-Kuehne F, Salama A, Workman S, Wrench D, Karim MY (2019) Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: systematic literature review. Autoimmun Rev 18(5):535–541. https://doi.org/10.1016/j.autrev.2019.03.010 CrossRefPubMed

105.

Lee S, Kim W, Seo W (2017) Safe use of rituximab in an elderly patient with rheumatoid arthritis and severe heart failure: a case report. J Clin Rheumatol:1. https://doi.org/10.1097/rhu.0000000000000648

106.

Sautner J, Rintelen B, Leeb BF (2013) Rituximab as effective treatment in a case of severe subcutaneous nodulosis in rheumatoid arthritis. Rheumatology (Oxford) 52(8):1535–1537. https://doi.org/10.1093/rheumatology/kes406 CrossRef

107.

Godot S, Gottenberg JE, Paternotte S, Pane I, Combe B, Sibilia J, Flipo RM, Schaeverbeke T, Ravaud P, Toussirot E, Berenbaum F, Mariette X, Wendling D, Sellam J (2013) Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry. Arthritis Care Res (Hoboken) 65(11):1874–1879. https://doi.org/10.1002/acr.22056 CrossRef

108.

Slimani S, Lukas C, Combe B, Morel J (2011) Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort. Joint Bone Spine 78(5):484–487. https://doi.org/10.1016/j.jbspin.2010.11.012 CrossRefPubMed

109.

Silva-Fernandez L, Lunt M, Kearsley-Fleet L, Watson KD, Dixon WG, Symmons DP, Hyrich KL (2016) The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-rheumatoid arthritis. Rheumatology (Oxford) 55(11):2033–2039. https://doi.org/10.1093/rheumatology/kew314 CrossRef

110.

Sokolovic S, Kasumagic S, Mackic-Durovic M, Aganovic-Musinovic I (2010) The impact of rituximab therapy on the chromosomes of patients with rheumatoid arthritis. Bosn J Basic Med Sci 10(2):121–124. https://doi.org/10.17305/bjbms.2010.2706 CrossRefPubMedPubMedCentral

111.

Diaz JC, Vallejo S, Canas CA (2012) Drug-induced lupus in anti-TNF-alpha therapy and its treatment with rituximab. Rheumatol Int 32(10):3315–3317. https://doi.org/10.1007/s00296-011-2137-y CrossRefPubMed

112.

Oldroyd AGS, Symmons DPM, Sergeant JC, Kearsley-Fleet L, Watson K, Lunt M, Hyrich KL (2018) Long-term persistence with rituximab in patients with rheumatoid arthritis. Rheumatology (Oxford) 57(6):1089–1096. https://doi.org/10.1093/rheumatology/key036 CrossRef

113.

Tavakolpour S (2017) Towards personalized medicine for patients with autoimmune diseases: opportunities and challenges. Immunol Lett 190:130–138. https://doi.org/10.1016/j.imlet.2017.08.002 CrossRefPubMed

114.

Kłak A, Paradowska-Gorycka A, Kwiatkowska B, Raciborski F (2016) Personalized medicine in rheumatology. Reumatologia 54(4):177–186. https://doi.org/10.5114/reum.2016.62472 CrossRefPubMedPubMedCentral

115.

Tavakolpour S, Darvishi M, Ghasemiadl M (2018) Pharmacogenetics: a strategy for personalized medicine for autoimmune diseases. Clin Genet 93(3):481–497. https://doi.org/10.1111/cge.13186 CrossRefPubMed

116.

Stradner MH, Dejaco C, Brickmann K, Graninger WB, Brezinschek HP (2016) A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study. Arthritis Res Ther 18:190. https://doi.org/10.1186/s13075-016-1091-1 CrossRefPubMedPubMedCentral

117.

Piantoni S, Scarsi M, Tincani A, Airo P (2015) Circulating CD4+ T-cell number decreases in rheumatoid patients with clinical response to rituximab. Rheumatol Int 35(9):1571–1573. https://doi.org/10.1007/s00296-015-3295-0 CrossRefPubMed

118.

Lurati A, Marrazza MG, Re KA, Scarpellini M (2009) Relationship between NK cell activation and clinical response in rheumatoid arthritis treated with rituximab. Int J Biomed Sci 5(2):92–95PubMedPubMedCentral

119.

Lurati A, Bertani L, Marrazza M, Re KA, Bompane D, Scarpellini M (2012) NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab. Biologics 6:83–87. https://doi.org/10.2147/btt.s29079 CrossRefPubMedPubMedCentral

120.

Parietti V, Chifflot H, Sibilia J, Muller S, Monneaux F (2010) Rituximab treatment overcomes reduction of regulatory iNKT cells in patients with rheumatoid arthritis. Clin Immunol 134(3):331–339. https://doi.org/10.1016/j.clim.2009.11.007 CrossRefPubMed

121.

Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loet X, Tebib J, Sibilia J, Taoufik Y, Dougados M, Mariette X (2011) B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 63(4):933–938. https://doi.org/10.1002/art.30233 CrossRefPubMed

122.

Sellam J, Riviere E, Courties A, Rouzaire PO, Tolusso B, Vital EM, Emery P, Ferraciolli G, Soubrier M, Ly B, Hendel Chavez H, Taoufik Y, Dougados M, Mariette X (2016) Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Res Ther 18(1):294. https://doi.org/10.1186/s13075-016-1190-z CrossRefPubMedPubMedCentral

123.

Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M (2013) Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital. Arthritis Care Res (Hoboken) 65(4):648–652. https://doi.org/10.1002/acr.21865 CrossRef

124.

Pyrpasopoulou A, Douma S, Triantafyllou A, Simoulidou E, Samara M, Parapanisiou E, Aslanidis S (2010) Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers. Mol Diagn Ther 14(1):43–48. https://doi.org/10.2165/11530570-000000000-00000 CrossRefPubMed

125.

Khan A, Scott DL, Batley M (2012) Smoking, rheumatoid factor status and responses to rituximab. Ann Rheum Dis 71(9):1587–1588. https://doi.org/10.1136/annrheumdis-2012-201758 CrossRefPubMed

126.

Gardette A, Ottaviani S, Tubach F, Roy C, Nicaise-Roland P, Palazzo E, Gill G, Meyer O, Dieude P (2014) High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis. Joint Bone Spine 81(5):416–420. https://doi.org/10.1016/j.jbspin.2014.06.001 CrossRefPubMed

127.

Jimenez Morales A, Maldonado-Montoro M, Martinez de la Plata JE, Perez Ramirez C, Daddaoua A, Alarcon Payer C, Exposito Ruiz M, Garcia Collado C (2019) FCGR2A/FCGR3A gene polymorphisms and clinical variables as predictors of response to tocilizumab and rituximab in patients with rheumatoid arthritis. J Clin Pharmacol 59(4):517–531. https://doi.org/10.1002/jcph.1341 CrossRefPubMed

128.

Fabris M, Quartuccio L, Lombardi S, Benucci M, Manfredi M, Saracco M, Atzeni F, Morassi P, Cimmino MA, Pontarini E, Fabro C, Pellerito R, Sarzi-Puttini P, Cutolo M, Carletto A, Bambara LM, Fischetti F, Curcio F, Tonutti E, De Vita S (2010) Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis. Reumatismo 62(4):253–258PubMed

129.

Daien CI, Fabre S, Rittore C, Soler S, Daien V, Tejedor G, Cadart D, Molinari N, Daures JP, Jorgensen C, Touitou I (2012) TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis. Joint Bone Spine 79(5):471–475. https://doi.org/10.1016/j.jbspin.2011.10.007 CrossRefPubMed

130.

Ruyssen-Witrand A, Rouanet S, Combe B, Dougados M, Le Loet X, Sibilia J, Tebib J, Mariette X, Constantin A (2013) Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients. Rheumatology (Oxford) 52(4):636–641. https://doi.org/10.1093/rheumatology/kes344 CrossRef

131.

Juge PA, Gazal S, Constantin A, Mariette X, Combe B, Tebib J, Dougados M, Sibilia J, Le Loet X, Dieude P (2017) Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis. RMD Open 3(2):e000448. https://doi.org/10.1136/rmdopen-2017-000448 CrossRefPubMedPubMedCentral

132.

Ruyssen-Witrand A, Rouanet S, Combe B, Dougados M, Le Loet X, Sibilia J, Tebib J, Mariette X, Constantin A (2012) Fcgamma receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 71(6):875–877. https://doi.org/10.1136/annrheumdis-2011-200337 CrossRefPubMed

133.

Sarsour K, Greenberg J, Johnston JA, Nelson DR, O'Brien LA, Oddoux C, Ostrer H, Pearlman A, Reed G (2013) The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-alpha antagonist therapies. Clin Exp Rheumatol 31(2):189–194PubMed

134.

Quartuccio L, Fabris M, Pontarini E, Salvin S, Zabotti A, Benucci M, Manfredi M, Biasi D, Ravagnani V, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Tomietto P, Bazzichi L, Saracco M, Pellerito R, Cimmino M, Schiavon F, Carraro V, Semeraro A, Caporali R, Cavagna L, Bortolotti R, Paolazzi G, Govoni M, Bombardieri S, De Vita S (2014) The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann Rheum Dis 73(4):716–721. https://doi.org/10.1136/annrheumdis-2012-202435 CrossRefPubMed

135.

Pal I, Szamosi S, Hodosi K, Szekanecz Z, Varoczy L (2017) Effect of Fcgamma-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis. RMD Open 3(2):e000485. https://doi.org/10.1136/rmdopen-2017-000485 CrossRefPubMedPubMedCentral

136.

Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, van de Wiel M, Dijkmans BA, Verweij CL, Voskuyl AE (2012) The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 14(2):R95. https://doi.org/10.1186/ar3819 CrossRefPubMedPubMedCentral

137.

de Jong TD, Sellam J, Agca R, Vosslamber S, Witte BI, Tsang ASM, Mantel E, Bijlsma JW, Voskuyl AE, Nurmohamed MT, Verweij CL, Mariette X (2017) A multi-parameter response prediction model for rituximab in rheumatoid arthritis. Joint Bone Spine 85:219–226. https://doi.org/10.1016/j.jbspin.2017.02.015 CrossRefPubMed

138.

Julia A, Barcelo M, Erra A, Palacio C, Marsal S (2009) Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells. Pharmacogenomics 10(10):1697–1708. https://doi.org/10.2217/pgs.09.99 CrossRefPubMed

139.

Duroux-Richard I, Pers YM, Fabre S, Ammari M, Baeten D, Cartron G, Touitou I, Jorgensen C, Apparailly F (2014) Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis. Mediat Inflamm 2014:342524–342529. https://doi.org/10.1155/2014/342524 CrossRef

140.

Tchetina EV, Pivanova AN, Markova GA, Lukina GV, Aleksandrova EN, Aleksankin AP, Makarov SA, Kuzin AN (2016) Rituximab downregulates gene expression associated with cell proliferation, survival, and proteolysis in the peripheral blood from rheumatoid arthritis patients: a link between high baseline autophagy-related ULK1 expression and improved pain control. Arthritis 2016:4963950–4963912. https://doi.org/10.1155/2016/4963950 CrossRefPubMedPubMedCentral

141.

Valleala H, Kauppi MJ, Kouri VP, Korpela M (2015) Epstein-Barr virus in peripheral blood is associated with response to rituximab therapy in rheumatoid arthritis patients. Clin Rheumatol 34(8):1485–1488. https://doi.org/10.1007/s10067-015-2992-0 CrossRefPubMed

142.

Chatzidionysiou K, Lukina G, Gabay C, Hetland ML, Hauge EM, Pavelka K, Nordstrom D, Canhao H, Tomsic M, Rotar Z, Lie E, Kvien TK, van Vollenhoven RF, Saevarsdottir S (2019) Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration. Scand J Rheumatol 48(1):17–23. https://doi.org/10.1080/03009742.2018.1466363 CrossRefPubMed

143.

Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P (2008) Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 58(10):2993–2999. https://doi.org/10.1002/art.23902 CrossRefPubMed

144.

Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, Davies BE (2007) Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 47(9):1119–1128. https://doi.org/10.1177/0091270007305297 CrossRefPubMed

145.

Ramwadhdoebe TH, van Baarsen LGM, Boumans MJH, Bruijnen STG, Safy M, Berger FH, Semmelink JF, van der Laken CJ, Gerlag DM, Thurlings RM, Tak PP (2019) Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatology (Oxford) 58(6):1075–1085. https://doi.org/10.1093/rheumatology/key428 CrossRef

146.

Lioger B, Edupuganti SR, Mulleman D, Passot C, Desvignes C, Bejan-Angoulvant T, Thibault G, Gouilleux-Gruart V, Melet J, Paintaud G, Ternant D (2017) Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. Br J Clin Pharmacol 83(8):1773–1781. https://doi.org/10.1111/bcp.13270 CrossRefPubMedPubMedCentral

147.

Sellam J, Marion-Thore S, Dumont F, Jacques S, Garchon HJ, Rouanet S, Taoufik Y, Hendel-Chavez H, Sibilia J, Tebib J, Le Loet X, Combe B, Dougados M, Mariette X, Chiocchia G (2014) Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial. Arthritis Rheumatol 66(8):2015–2025. https://doi.org/10.1002/art.38671 CrossRefPubMed

148.

Tony HP, Roll P, Mei HE, Blumner E, Straka A, Gnuegge L, Dorner T (2015) Combination of B cell biomarkers as independent predictors of response in patients with rheumatoid arthritis treated with rituximab. Clin Exp Rheumatol 33(6):887–894PubMed

149.

Brezinschek HP, Rainer F, Brickmann K, Graninger WB (2012) B lymphocyte-typing for prediction of clinical response to rituximab. Arthritis Res Ther 14(4):R161. https://doi.org/10.1186/ar3901 CrossRefPubMedPubMedCentral

150.

Fabris M, De Vita S, Blasone N, Visentini D, Pezzarini E, Pontarini E, Fabro C, Quartuccio L, Mazzolini S, Curcio F, Tonutti E (2010) Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. Auto Immun Highlights 1(2):87–94. https://doi.org/10.1007/s13317-010-0013-5 CrossRefPubMedPubMedCentral

151.

Roodenrijs NMT, de Hair MJH, Wheater G, Elshahaly M, Tekstra J, Teng YKO, Lafeber F, Hwang CC, Liu X, Sasso EH, van Laar JM (2018) The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies. Arthritis Res Ther 20(1):256. https://doi.org/10.1186/s13075-018-1750-5 CrossRefPubMedPubMedCentral

152.

Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loet X, Combe B, Dougados M, Mariette X, Taoufik Y (2011) Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 63(12):3692–3701. https://doi.org/10.1002/art.30599 CrossRefPubMed

153.

M'Barek RB, Dupre T, Tubach F, Dieude P, Palazzo E, Hayem G, Dawidowicz K, Ottaviani S, Alfaiate T, Lecon-Malais V, Boutten A, Meyer O (2014) 25-hydroxyvitamin D status does not affect the clinical rituximab response in rheumatoid arthritis. Joint Bone Spine 81(1):96–97. https://doi.org/10.1016/j.jbspin.2013.04.017 CrossRefPubMed

154.

Riviere E, Sellam J, Pascaud J, Ravaud P, Gottenberg JE, Mariette X (2018) Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis. Arthritis Res Ther 20(1):122. https://doi.org/10.1186/s13075-018-1628-6 CrossRefPubMedPubMedCentral

155.

Nakayamada S, Tanaka Y (2016) BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. Inflammation and Regeneration 36(1):6. https://doi.org/10.1186/s41232-016-0015-4 CrossRefPubMedPubMedCentral

156.

Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A (2013) A critical review of the role of fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol 6:1–1. https://doi.org/10.1186/1756-8722-6-1 CrossRefPubMedPubMedCentral

157.

Canestri S, Totaro MC, Serone E, Tolusso B, Frezza D, Gremese E, Ferraccioli G (2012) Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients. Reumatismo 64(6):368–373. https://doi.org/10.4081/reumatismo.2012.368 CrossRefPubMed

158.

Viecceli D, Garcia MP, Schneider L, Alegretti AP, Silva CK, Ribeiro AL, Brenol CV, Xavier RM (2017) Correlation between cellular expression of complement regulatory proteins with depletion and repopulation of B-lymphocytes in peripheral blood of patients with rheumatoid arthritis treated with rituximab. Rev Bras Reumatol Engl Ed 57(5):385–391. https://doi.org/10.1016/j.rbre.2016.09.007 CrossRefPubMed

159.

Henry C, Deschamps M, Rohrlich PS, Pallandre JR, Remy-Martin JP, Callanan M, Traverse-Glehen A, GrandClement C, Garnache-Ottou F, Gressin R, Deconinck E, Salles G, Robinet E, Tiberghien P, Borg C, Ferrand C (2010) Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance. Blood 115(12):2420–2429. https://doi.org/10.1182/blood-2009-06-229112 CrossRefPubMed

160.

Gamonet C, Deschamps M, Marion S, Herbein G, Chiocchia G, Auger I, Saas P, Ferrand C, Toussirot E (2015) The alternative CD20 transcript variant is not a surrogate marker for resistance to rituximab in patients with rheumatoid arthritis. Rheumatology (Oxford) 54(9):1744–1745. https://doi.org/10.1093/rheumatology/kev210 CrossRef

161.

Schroder C, Azimzadeh AM, Wu G, Price JO, Atkinson JB, Pierson RN (2003) Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol 12(1):19–28. https://doi.org/10.1016/s0966-3274(03)00059-5 CrossRefPubMed

162.

Kane SV, Acquah LA (2009) Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 104(1):228–233. https://doi.org/10.1038/ajg.2008.71 CrossRefPubMed

163.

Chakravarty EF, Murray ER, Kelman A, Farmer P (2011) Pregnancy outcomes after maternal exposure to rituximab. Blood 117(5):1499–1506. https://doi.org/10.1182/blood-2010-07-295444 CrossRefPubMed

164.

Gualtierotti R, Ingegnoli F, Meroni PL (2013) Pre-conceptional exposure to rituximab: comment on the article by Ojeda-Uribe et al. Clin Rheumatol 32(5):727–728. https://doi.org/10.1007/s10067-013-2241-3 CrossRefPubMed

165.

Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N, Dolhain R, Forger F, Khamashta M, Ruiz-Irastorza G, Zink A, Vencovsky J, Cutolo M, Caeyers N, Zumbuhl C, Ostensen M (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795–810. https://doi.org/10.1136/annrheumdis-2015-208840 CrossRefPubMed

166.

Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K, Arthanari S, Cunningham J, Flanders L, Moore L, Crossley A, Purushotham N, Desai A, Piper M, Nisar M, Khamashta M, Williams D, Gordon C, Giles I (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 55(9):1693–1697. https://doi.org/10.1093/rheumatology/kev404 CrossRef

167.

Pham T, Fautrel B, Gottenberg JE, Goupille P, Hachulla E, Masson C, Morel J, Mouthon L, Saraux A, Schaeverbeke T, Wendling D, Mariette X, Sibilia (2008) Rituximab (MabThera) therapy and safety management. Clinical tool guide. Joint Bone Spine 75 Suppl 1:S1–99. https://doi.org/10.1016/s1297-319x(08)73620-0

168.

De Cock D, Birmingham L, Watson KD, Kearsley-Fleet L, Symmons DP, Hyrich KL (2017) Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab. Rheumatology (Oxford) 56(4):661–663. https://doi.org/10.1093/rheumatology/kew493 CrossRef

169.

Ojeda-Uribe M, Afif N, Dahan E, Sparsa L, Haby C, Sibilia J, Ternant D, Ardizzone M (2013) Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol 32(5):695–700. https://doi.org/10.1007/s10067-012-2156-4 CrossRefPubMed

170.

Bae SC, Lee YH (2019) Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis. Int J Clin Pharmacol Ther 57(4):188–196. https://doi.org/10.5414/cp203360 CrossRefPubMed

171.

Tony HP, Kruger K, Cohen SB, Schulze-Koops H, Kivitz AJ, Jeka S, Vereckei E, Cen L, Kring L, Kollins D (2019) Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken) 71(1):88–94. https://doi.org/10.1002/acr.23771 CrossRef

172.

Park W, Bozic-Majstorovic L, Milakovic D, Berrocal Kasay A, El-Khouri EC, Irazoque-Palazuelos F, Molina FFC, Shesternya P, Miranda P, Medina-Rodriguez FG, Wiland P, Jeka S, Chavez-Corrales J, Garmish O, Linde T, Rekalov D, Hrycaj P, Krause A, Fomina N, Piura O, Abello-Banfi M, Suh CH, Shim SC, Lee SJ, Lee SY, Kim SH, Yoo DH (2018) Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled phase 3 trial. MAbs 10(6):934–943. https://doi.org/10.1080/19420862.2018.1487912 CrossRefPubMedPubMedCentral

173.

Suh CH, Yoo DH, Berrocal Kasay A, Chalouhi El-Khouri E, Cons Molina FF, Shesternya P, Miranda P, Medina-Rodriguez FG, Wiland P, Jeka S, Chavez-Corrales J, Linde T, Hrycaj P, Abello-Banfi M, Hospodarskyy I, Jaworski J, Piotrowski M, Brzosko M, Krogulec M, Shevchuk S, Calvo A, Andersone D, Park W, Shim SC, Lee SJ, Lee SY (2019) Long-term efficacy and safety of biosimilar CT-P10 versus innovator rituximab in rheumatoid arthritis: 48-week results from a randomized phase III trial. BioDrugs 33(1):79–91. https://doi.org/10.1007/s40259-018-00331-4 CrossRefPubMedPubMedCentral

174.

Shim SC, Bozic-Majstorovic L, Berrocal Kasay A, El-Khouri EC, Irazoque-Palazuelos F, Cons Molina FF, Medina-Rodriguez FG, Miranda P, Shesternya P, Chavez-Corrales J, Wiland P, Jeka S, Garmish O, Hrycaj P, Fomina N, Park W, Suh CH, Lee SJ, Lee SY, Bae YJ, Yoo DH (2019) Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized phase 3 trial. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/kez152

175.

Cohen SB, Burgos-Vargas R, Emery P, Jin B, Cronenberger C, Vazquez-Abad MD (2018) Extension study of PF-05280586, a potential rituximab biosimilar, versus rituximab in subjects with active rheumatoid arthritis. Arthritis Care Res (Hoboken) 70(11):1598–1606. https://doi.org/10.1002/acr.23586 CrossRef

Titel: A comprehensive review of rituximab therapy in rheumatoid arthritis patients
verfasst von: Soheil Tavakolpour
Samira Alesaeidi
Mohammad Darvishi
Mojtaba GhasemiAdl
Sahar Darabi-Monadi
Meisam Akhlaghdoust
Somayeh Elikaei Behjati
Arash Jafarieh
Publikationsdatum: 01.08.2019
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 11/2019
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-019-04699-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2019

LncRNA GAS5 overexpression downregulates IL-18 and induces the apoptosis of fibroblast-like synoviocytes

Neuropathic-like pain in psoriatic arthritis: evidence of abnormal pain processing

Increased risks of psychiatric disorders in patients with primary Sjögren’s syndrome—a secondary cohort analysis of nationwide, population-based health claim data

Acroosteolysis and bone metabolism parameters distinguish female patients with limited systemic sclerosis with and without calcinosis: a case control study

Predictors of damage accrual in systemic lupus erythematosus: a longitudinal observational study with focus on neuropsychological factors and anti-neuronal antibodies